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An Ethical Defense of Federal Funding for Human
Embryonic Stem Cell Research
James F. Childress, Ph.D.*t
Should the Federal Government fund human embryonic stem cell
research? In addressing this question and answering it affirmatively, I will
draw from testimony I was asked to prepare for the Hearing on "Stem Cell
Research" conducted by the U.S. Senate Committee on Health, Education,
Labor and Pensions, chaired by Senator Edward M. Kennedy, on
September 5, 2001. Even though I did not testify on that occasion on
behalf of the National Bioethics Advisory Commission (NBAC), on which I
served until its demise at the end of September 2001, I drew, then as well
as now, on the NBAC's 1999 report on Ethical Issues in Human Stem Cell
Research, which, as a commissioner, I helped to prepare and also endorsed.
I. A RANGE OF ETHICALLY ACCEPTABLE POLICIES
Despite the thought and consideration that went into President Bush's
announced policy on the use of federal funds in human embryonic stem
cell research, I would argue that more flexible policies are ethically
acceptable and even preferable. Three options merit consideration:
(1) Providing federal funds for research on cell lines derived (using non-
federal funds) from embryos prior to August 9, 2001 within certain
ethical guidelines (President Bush's announced policy).
(2) Providing federal funds for research on cell lines derived (using non-
federal funds) from embryos, earlier or in the future, within certain
ethical guidelines (the policy proposed earlier by the National Institutes
of Health (NIH)).
* James F. Childress is the Kyle Professor of Religious Studies, Professor of Medical
Education, and Director of the Institute for Practical Ethics at the University of Virginia.
t I am grateful to Alta Charo and LeRoy Walters for their thoughtful and helpful comments
on an earlier draft; they are absolved of any responsibility for its content. Portions of this
Article will appear, in modified form, in a forthcoming commentary in the American
Journal of Bioethics.
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(3) Providing federal funds for both the derivation of, and research on,
cell lines derived from embryos within certain ethical guidelines (NBAC's
recommendation).
President Bush's announced policy (option 1) suggests that it is
ethically acceptable to use federal funds for research on stem cell lines that
were derived, using non-federal funds, prior to his announcement on
August 9, if the derivation also met certain ethical requirements, including
the informed consent of donors of embryos created solely for reproductive
purposes and the absence of financial inducements. 2 If policy option 1 is
ethically acceptable-as I believe it is-then it should also be ethically
acceptable to do the same thing prospectively (policy option 2). That is, it
should be ethically acceptable to provide federal funds for research on
stem cell lines derived in the future, after August 9 as well as before, with
non-federal funds and within the same ethical guidelines. This prospective
policy would offer greater-and needed-flexibility for the short-term and
long-term future. And it would be ethically preferable because it would
increase the possibilities for important research, without violating relevant
ethical standards.
President Bush's statement noted that the first policy (option 1),
which includes about sixty stem cell lines (about which there is
considerable scientific uncertainty and controversy4), "allows us to explore
the promise and potential of stem cell research without crossing a
fundamental moral line by providing taxpayer funding that would sanction
or encourage further destruction of human embryos that have at least the
potential for life."5 However, I believe that ethically we can provide federal
tax funds for research on stem cells derived after as well as before August
9, using non-federal funds, and that this can be accomplished without
sanctioning or encouraging further destruction of human embryos. To do
so, we must establish effective ethical safeguards. Those safeguards should
ensure, to the greatest extent possible, the couple's voluntary and
informed decision to destroy their embryos-rather than use them or
donate them to another couple-and their voluntary and informed
decision to donate them for research. Each decision should be free of
financial inducement. In view of the couple's decision to destroy the
embryos, the research would only determine how the destruction occurs,
not whether it will occur; as matters stand in most jurisdictions, couples may
determine how to dispose of their embryos.
It is possible to go further than either of these first two policies and
recommend, as the NBAC did, a third option-the provision of federal
funds for both the derivation of stem cells from embryos and research on
11:1 (2001)
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those cell lines, again in accord with ethical requirements. One argument
for this option is that a strict separation between derivation and use would
adversely affect the development of scientific knowledge. For instance, the
methods for deriving embryonic stem cells may affect their properties, and
scientists may increase their understanding of the nature of such cells in
the process of deriving them.6
In short, I see no ethical reason for limiting federal funding to
research with cell lines derived by some arbitrary date, as long as we can
ensure that future derivation, with non-federal funds (option 2) or federal
funds (option 3), also respects the same moral limits. Indeed, our
collective moral duty to alleviate human suffering and reduce the number
of premature deaths provides a strong ethical reason to support this
research, within moral limits.
II. RESPECT FOR THE EMBRYO
There is widespread agreement, as the NBAC observed, that "human
embryos deserve respect as a form of human life," but at the same time,
sharp disagreements exist "regarding both what form such respect should
take and what level of protection is required at different stages of
embryonic development."7 At the very least this "respect" implies that:
" Early embryos should not be used unless they are necessary for
research;
" embryos remaining after in vitro fertilization (IVF), as well as
cadaveric fetal tissue, should not be bought or sold; and
* alternative sources of stem cells should simultaneously be
explored.
Indeed, given the promise of this research, and the uncertainty about
which stem cells might be adequate and which might be superior for
various purposes, research on stem cells derived from. different sources
should be eligible for federal funding. The goal of realizing the
therapeutic promise of stem cell research is ethically significant. It is also
ethically important to treat the different sources of stem cells with
appropriate respect.
One interpretation of appropriate respect for early embryos would
rule out their deliberate creation in order to use them in research. I
supported the NBAC's recommendation that, at this time, federal agencies
should not fund research involving the derivation or use of embryonic
stem cells from embryos made solely for research purposes, whether they
were made by IVF or by somatic cell nuclear transfer into oocytes.
However, in this area, it is ethically dangerous to say "never," and the
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Senate should not accept the House ban on so-called "therapeutic cloning"
(in contrast to "reproductive cloning"). For now, it appears to be possible
to develop enough cell lines without creating more embryos, and there
appears to be no need for nuclear transfer unless and until therapy is
possible. But if therapy becomes possible, matched tissue may be needed.
And it may then be necessary to revisit the question about so-called
"therapeutic cloning,"" which at the present is really experimental research
rather than therapeutic.
III. DIvERsITY OF RELIGIOUS AND SECULAR VIEWS
Views about appropriate respect for the embryo hinge on convictions
about the embryo's moral status. As a specialist in religious ethics, I have
been fascinated by the diverse religious views on human embryonic stem
cell research, both across traditions and within traditions. On May 7, 1999
the NBAC convened a meeting at Georgetown University to hear
presentations on religious perspectives relating to human stem cell
research. Eleven scholars in Roman Catholic, Jewish, Eastern Orthodox,
Islamic, and Protestant traditions presented formal testimony that day, and
two others made statements in the public comment period. Their
statements, as well as later statements of other traditions (e.g., the Mormon
tradition), reveal significantly different perspectives on the ethical
acceptability of research on unimplanted human embryos. Even when
similarly opposed to abortion, different religious positions may reach
divergent moral conclusions about human embryonic stem cell research.
Their different conclusions follow, in part, from different premises about
the moral status of the early embryo existing outside a woman's womb.
Although Roman Catholicism officially opposes human embryonic
stem cell research, some Roman Catholic moral theologians endorse it. A
number of Jewish thinkers hold that the extracorporeal embryo, in the
petri dish or cryopreserved, does not have standing in Jewish law and that
it is justifiable to go forward with embryonic stem cell research. Protestants
represent a wide range of views, as could be expected in view of the more
than two hundred denominations in the United States that are identified
as Protestant. Some Muslim thinkers also accept embryonic stem cell
research.9
An interesting case in point is the Church of Jesus Christ of the Latter
Day Saints (Mormons), which generally joins the Roman Catholic Church
in strong opposition to abortion, but which has officially stated its
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The proclaimed potential to provide cures or treatments for many
serious diseases needs careful and continuing study by conscientious,
qualified investigators. As with any emerging new technology, there are
concerns that must be addressed. Scientific and religious viewpoints both
demand that strict moral and ethical guidelines be followed.'
The five Mormon senators support federal funding for embryonic
stem cell research, without compromising their "pro-life" stance. The
Mormon tradition does not rest its opposition to abortion on a declaration
about when human life begins-it views abortion as similar to homicide. It
holds that each person existed as a spirit child of God prior to receiving a
physical body on earth. Thus, in what is a two-step process of creation-
spirit and flesh-the union of spirit and body marks the beginning of life
on earth. In this context, stem cells may be comparable to the "dust of the
earth," essential to human life but not human life itself."
In brief, no consensus exists among religious traditions-or secular
moral traditions-about the moral status of the extracorporeal embryo.
This diversity sets the context for an ethical assessment of public policy
toward human embryonic stem cell research. An ethical public policy in
our pluralistic society has to respect diverse fundamental beliefs. And yet it
must not be held hostage to any single view of embryonic life.
IV. STEM CELL LINES DERIVED FROM ABORTED FETUSES
Another possible source of stem cells-human embryonic germ cells
from aborted fetuses-has received scant attention recently. 12 However,
precedent exists in U.S. policies for providing federal funds to support
research on cell lines derived from aborted fetuses. This precedent appears
in the framework developed for the use of cadaveric fetal tissue in
transplantation research. 13 This framework seeks to separate as much as
possible a pregnant woman's decision to abort from her decision to donate
fetal tissue for research. The rationale for this separation is to avoid any
possibility, however slight, that the opportunity to donate fetal tissue in
federally funded research could provide an additional incentive for a
woman to have an abortion.
Several "ethical safeguards" were erected in order to prevent the use of
fetal tissue in federally funded transplantation research from encouraging
abortions. For example, these safeguards separate the consent process for
abortion from the consent process for the donation of fetal tissue for
research, and prohibit the donor of fetal tissue from designating the
recipient of the transplant. These ethical guidelines, which appear to have
been effective in human fetal tissue transplantation research, should now
5
Childress: An Ethical Defense of Federal Funding
Published by Yale Law School Legal Scholarship Repository, 2002
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
be extended to stem cell research as well, as the NBAC has recommended
and the NIH has proposed. 4 Even if at this juncture embryonic stem cells
appear to be more promising than embryonic germ cells, derived from
aborted fetuses, it would be appropriate to ensure that the current
guidelines for the use of fetal tissue in federally funded research
adequately cover research on embryonic germ cell lines. However, in the
absence of a strongly felt need to use germ cells from aborted fetuses, the
political reluctance to get embroiled in abortion wars may prevent such an
action.
V. ANOTHER APPROACH TO PUBLIC POLICY-THE U.K. EXPERIENCE
The United Kingdom has responded quite differently than the United
States to human embryonic stem cell research, including so-called
"therapeutic cloning." Following the 1984 Warnock Committee report, the
British government implemented most of that Committee's
recommendations in the 1990 Human Fertilisation and Embryology Act,
which, among other things, established the Human Fertilisation and
Embryology Authority (HFEA).15 Over the last decade, the HFEA, currently
chaired by Ruth Deech, has had authority over IVF, in policy and in
practice. The HFEA also licenses and monitors all human embryo research
in the United Kingdom, whatever the source of funding. In addition, it
approves, in limited circumstances, the creation of embryos for research
purposes. More than 53,000 embryos have been used in research, while
118 have been created specifically for research.16 In January 2001, following
vigorous public debate, the British Parliament approved regulations to
enlarge the range of acceptable goals for human embryo research and also
to permit the creation of embryos for research by nuclear transfer
("therapeutic cloning")."
In the United Kingdom, then, years prior to the recent debate about
stem cell research, several substantive and procedural standards were
established for embryo research, including the creation of embryos for
research. Furthermore, the public appears to have considerable
confidence in that framework, based on a decade's experience. As a result,
the acceptance of "therapeutic cloning" required only an extension of the
existing framework, rather than the invention of a new one.
The U.K's strict regulation of reproductive technologies and
authorization, but also tight control over, embryo research appears to have
created a context for a positive response to the possibilities of human stem
cell research.' By contrast, in the United States, regulation of reproductive
technologies and fertility clinics, which is under the control of the states, is,
at best, limited and uneven, and the federal government has not allowed
11:1 (2001)
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the use of federal funds for embryo research (though, of course, privately
funded research proceeds). As a result, the task of formulating public
policy toward human embryonic stem cell research is much more
challenging in the United States.
CONCLUSION
If President Bush's announced policy is ethically acceptable, as I
believe it is, there is no cogent ethical reason for stopping where his policy
stops-with the use of stem cell lines that were derived from embryos by
August 9, 2001. Indeed, that temporal restriction is difficult to defend from
an ethical standpoint. It is possible to use non-federal funds (or even, I
would argue, federal funds) to derive stem cell lines from embryos within
certain ethical requirements, and to provide federal funds for research on
those lines without sanctioning or encouraging the destruction of embryos
or the creation of so-called "extra" or "surplus" embryos in clinical IVF. I
would support these other policy options-derivation with non-federal
funds or with federal funds-on the grounds that they will probably enable
important research to proceed more rapidly, and will not breach crucial
ethical boundaries. In addition, it is ethically justifiable to provide federal
funds for deriving and conducting research on stem cell lines developed
from aborted fetuses, in accord with the guidelines and regulations already
established for human fetal tissue transplantation research.
Whichever policies are adopted to enable important and promising
stem cell research to go forward, within ethical limits, we will need a strong
public body to review protocols for deriving stem cells from embryos (and
from fetal tissue) and to monitor this research.' 9 Perhaps the Council on
Bioethics, which President Bush has announced, could fulfill these
functions, but it is not yet clear what its mandate and structure will be. If it
does not fulfill these functions, some other public body will be needed, as
the U.K. experience suggests. In the United Kingdom, the HFEA is
statutorily established, and that might be a model for the United States,
because we also need oversight of human embryo research in the private
arena.
It is safe to assume that no policy currently under discussion will be the
final one. We will need to revisit this research again and again as the
science develops and as its ethical implications become clearer, particularly
through a public body's on-going review and oversight. Thus, no policy will
end the national conversation about how to balance, over time, the
relevant ethical considerations. Our public dialogue needs to continue
with as much rigor and imagination as possible. As we continue to reflect
on the important issues raised by human embryonic stem cell research, we
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need a policy with greater flexibility than the one President Bush
announced, but also with close review and oversight.
In a recent editorial in Science, ethicist LeRoy Walters stressed that
"Governments and their advisors will need to be humble and flexible, but
also decisive and courageous." ° We must carefully scrutinize claims of
scientific promise, being wary of unfounded optimism, but we must not
neglect research that offers a significant prospect of major medical
breakthroughs that may alleviate human suffering and reduce the number
of premature deaths. As a society, we must provide clear and strong ethical
guidelines, regulations, and safeguards for stem cell research, while
avoiding unreasonably rigid rules that appear to be arbitrary and
inconsistent.
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